REG-Sutherland Health Group Plc: Trading Statement

11 November 2009

SUTHERLAND HEALTH GROUP PLC
("Sutherland Health Group" or "the Company")
PLUS Symbol: SHGP

Interim results update and SHG delivers a maiden interim profit

The Board of Sutherland Health Group, a national supplier of patient hygiene
and sexual health products to customers including the NHS, announces that the
business for the six months to 30th September 2009 has shown continued growth.
The full interim results for the period will be announced on Monday 16th
November 2009.

Reported sales in the period were £469,089 (2008: £409,850), up 14% on the same
period last year.

Gross Profit rose by 20% to £240,383 (2008: £200,206)

The Company is also pleased to announce that it has made a maiden interim
profit during the period of £7,245 (2008: Loss of £57,821)

Commenting on the news Chairman John French said:

"I am delighted to report that we have reached the important milestone of
delivering a maiden interim profit. The Company has shown consistent growth in
customers and in their interest in the range of products that we have
developed. We look forward to updating shareholders on further new developments
that should see our current growth trend continue"

The Directors of the Issuer accept responsibility for this announcement.

Enquiries:
Sutherland Health Group plc
John French, Chairman
E: john@sutherlandhealth.com
T: 07836 722 482

Bridge Hall Stockbrokers Limited
Alex Benger
E: corpfin@bridgehall.co.uk
T: 020 7337 9705

Bishopsgate Communications Ltd.
Maxine Barnes
E: shg@bishopsgatecommunications.com
T: 020 7562 3367

Notes to Editors:
Sutherland Health Group Plc is a national supplier of patient hygiene, sexual
health and diagnostic products to the UK National Health Service (NHS) and
other UK customers. Its aim is to supply innovative solutions to current health
issues by studying current trends and working alongside leading professionals
who also work within the health sector.

The company is committed to developing and marketing high quality brands and
products that will benefit health professionals and consumers alike in many
areas of health. The Group has established its own brands Condomania® Condoms,
Sutherland® Lubricating Jelly and Vision® pregnancy diagnostics that have
already become established within the NHS business.

The Company has also developed the Sutherland® patient hygiene range which is
now on contract with NHS England and NHS Northern Ireland that can reduce the
risk to patients of cross infection.

The Group is ISO and MHRA registered, and at present principally operates
within the United Kingdom.

For further information on the Company visit www.sutherlandhealth.com

END